Kolmar BioTech (215380) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Kolmar BioTech (215380) reported revenue of 37.6 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202537.6 billion KRW-3.9 billion KRW-5.5 billion KRW[source]
202443.2 billion KRW1.8 billion KRW225 million KRW[source]
202338.6 billion KRW-4.5 billion KRW-5.1 billion KRW[source]
202246.9 billion KRW-2.5 billion KRW-1.9 billion KRW[source]
202131.2 billion KRW-3.5 billion KRW-1.9 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202586.8 billion KRW63.4 billion KRW23.4 billion KRW[source]
202494.7 billion KRW65.3 billion KRW29.4 billion KRW[source]
202398.3 billion KRW76.4 billion KRW22.0 billion KRW[source]
202295.0 billion KRW65.3 billion KRW29.7 billion KRW[source]
2021100.1 billion KRW68.7 billion KRW31.5 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice